Inhaled Heparin for Hospitalised COVID-19 Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This meta-trial is a prospective collaborative individual participant data meta-analysis of
randomised controlled trials and early phase studies. Individual studies will be conducted in
multiple countries, including Australia, the UK, the USA, Ireland, Argentina, Brazil and
Egypt.
Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not
require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or
standard care for up to 21 days or until the patient has no respiratory symptoms. All studies
will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion
of patients who receive invasive mechanical ventilation censored at day 28. Individual
studies may have specific outcome measures in addition to the core set.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Australian National University
Collaborators:
Clinica San Camilo, Argentina Coney Island Hospital, Brooklyn, NY Frederick Health Galeno Desenvolvimento de Pesquisas Clínicas Helwan University